- Self-Study Guided Program o Notes o Tests o Videos o Action Plan
Photo: Twitter/@WHO
The World Health Organisation has endorsed TrueNat, an indigenous molecular diagnostic tool for tuberculosis (TB) diagnosis. The disease remains a threat to public health and is the top infectious cause of death globally.
In 2018, an estimated 10 million people developed TB and 1.5 million died of it while at least a million children become ill with it every year. Also about 5,00,000 new cases of multidrug 2 and rifampicin-resistant tuberculosis (MDR/RR-TB) are estimated to emerge annually but only one in three cases was reported by countries to have been diagnosed and treated in 2018.
WHO has noted that since the approval of Xpert MTB/RIF in 2010, significant additional evidence has been generated on its use as initial test for the diagnosis and rifampicin-resistant TB.
“In recent months new data on the use of Xpert and on the latest version TrueNat MTB and MTB Plus system have also become available. WHO commissioned a systematic review of all the available data in 2019. The results were assessed during a meeting of an independent WHO-convened Guideline Development Group (GDG) on 3-6 December 2019. Detailed recommendations will be published as part of updated WHO Consolidated Guidelines on TB diagnosis in 2020,’’ noted WHO.
You have reached your limit for free articles this month.
Register to The Hindu for free and get unlimited access for 30 days.
Already have an account ? Sign in
Sign up for a 30-day free trial. Sign Up
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Enjoy reading as many articles as you wish without any limitations.
A select list of articles that match your interests and tastes.
Move smoothly between articles as our pages load instantly.
A one-stop-shop for seeing the latest updates, and managing your preferences.
We brief you on the latest and most important developments, three times a day.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
Why you should pay for quality journalism - Click to know more
Please enter a valid email address.
Subscribe to The Hindu now and get unlimited access.
Already have an account? Sign In
Sign up for a 30-day free trial. Sign Up
To continue enjoying The Hindu, You can turn off your ad blocker or Subscribe to The Hindu.